Interleukin 1 (IL1) - Pipeline Review, H2 2017

  • ID: 4429836
  • Drug Pipelines
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Exicure Inc
  • Novartis AG
  • Opsona Therapeutics Ltd
  • Orphit SAS
  • Pfizer Inc
  • MORE
Interleukin 1 (IL1) - Pipeline Review, H2 2017

Summary

Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.

Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5, 2, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Musculoskeletal Disorders, Metabolic Disorders, Oncology, Cardiovascular, Dermatology, Central Nervous System, Gastrointestinal, Genetic Disorders, Ear Nose Throat Disorders and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Epidermolysis Bullosa, Inflammation, Non-Small Cell Lung Cancer, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Rheumatoid Arthritis, Type 2 Diabetes, Acne Vulgaris, Alzheimer's Disease, Autoimmune Disorders, Bladder Cancer, Bullous Pemphigoid, Cachexia, Cardiovascular Risk Factors, Cervical Cancer, Colorectal Cancer, Dermatological Disorders, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Inflammatory Bowel Disease, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Osteoarthritis, Ovarian Cancer, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Sarcoidosis, Skin Inflammation, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).

The latest report Interleukin 1 (IL1) - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
  • The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Exicure Inc
  • Novartis AG
  • Opsona Therapeutics Ltd
  • Orphit SAS
  • Pfizer Inc
  • MORE
Introduction

Interleukin 1 (IL1) - Overview

Interleukin 1 (IL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 (IL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 (IL1) - Companies Involved in Therapeutics Development

AbbVie Inc

Apexigen Inc

Exicure Inc

Immune Response BioPharma Inc

Moderna Therapeutics Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Orphit SAS

Peptinov SAS

Pfizer Inc

R Pharm

Regeneron Pharmaceuticals Inc

Spherium Biomed SL

Swedish Orphan Biovitrum AB

XBiotech Inc

Interleukin 1 (IL1) - Drug Profiles

ABT-981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-4161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-2752 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMN-54 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPV-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilonacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suramin hexasodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xilonix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ymalzen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 (IL1) - Dormant Products

Interleukin 1 (IL1) - Discontinued Products

Interleukin 1 (IL1) - Product Development Milestones

Featured News & Press Releases

Nov 03, 2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions

Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting

Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America

Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board

Sep 27, 2017: Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research

Sep 15, 2017: Refusal of the marketing authorization for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech

Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Aug 27, 2017: Anti-inflammatory drug could reduce risk of second heart attack

Aug 27, 2017: Anti-Inflammatory Therapy Cuts Risk of Lung Cancer

Aug 27, 2017: Inflammatory Hypothesis Confirmed: Reducing Inflammation Without Lowering Cholesterol Cuts Risk of Cardiovascular Events

Aug 27, 2017: Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned

Aug 27, 2017: Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk

Aug 07, 2017: Novartis’s Ilaris Rejects For Use Within NHS Scotland

Jun 22, 2017: Novartis Phase III study shows ACZ885 reduces cardiovascular risk in people who survived a heart attack

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AbbVie Inc, H2 2017

Pipeline by Apexigen Inc, H2 2017

Pipeline by Exicure Inc, H2 2017

Pipeline by Immune Response BioPharma Inc, H2 2017

Pipeline by Moderna Therapeutics Inc, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Omnitura Therapeutics Inc, H2 2017

Pipeline by Opsona Therapeutics Ltd, H2 2017

Pipeline by Optimum Therapeutics LLC, H2 2017

Pipeline by Orphit SAS, H2 2017

Pipeline by Peptinov SAS, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by R Pharm, H2 2017

Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Pipeline by Spherium Biomed SL, H2 2017

Pipeline by Swedish Orphan Biovitrum AB, H2 2017

Pipeline by XBiotech Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Dormant Products, H2 2017 (Contd..3), H2 2017

Dormant Products, H2 2017 (Contd..4), H2 2017

Discontinued Products, H2 2017

Discontinued Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017 (Contd..2), H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Apexigen Inc
  • Exicure Inc
  • Immune Response BioPharma Inc
  • Moderna Therapeutics Inc
  • Novartis AG
  • Omnitura Therapeutics Inc
  • Opsona Therapeutics Ltd
  • Optimum Therapeutics LLC
  • Orphit SAS
  • Peptinov SAS
  • Pfizer Inc
  • R Pharm
  • Regeneron Pharmaceuticals Inc
  • Spherium Biomed SL
  • Swedish Orphan Biovitrum AB
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll